Crinetics Pharmaceuticals

OverviewSuggest Edit

Crinetics Pharmaceuticals Inc. discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. All Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

TypePublic
Founded2008
HQSan Diego, CA, US
Websitecrinetics.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Feb 2019)47(+47%)
Job Openings15
Revenue (FY, 2020)$71 K(-94%)
Cybersecurity ratingAMore

Key People/Management at Crinetics Pharmaceuticals

R. Scott Struthers

R. Scott Struthers

Founder & Chief Executive Officer
Marc Wilson

Marc Wilson

Chief Financial Officer
Alan S. Krasner

Alan S. Krasner

Chief Medical Officer
Stephen F. Betz

Stephen F. Betz

Founder & Vice President, Biology
Ajay Madan

Ajay Madan

Chief Development Officer
Gina Ford

Gina Ford

Vice President, Corporate Strategy & Commercial Planning
Show more

Crinetics Pharmaceuticals Office Locations

Crinetics Pharmaceuticals has an office in San Diego
San Diego, CA, US (HQ)
10222 Barnes Canyon Rd Building #2
Show all (1)

Crinetics Pharmaceuticals Financials and Metrics

Crinetics Pharmaceuticals Revenue

Crinetics Pharmaceuticals's revenue was reported to be $71 k in FY, 2020
USD

Net income (Q1, 2021)

(22.9m)

EBIT (Q1, 2021)

(22.9m)

Cash (31-Mar-2021)

105.6m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

589.0k2.0m2.4m1.2m71.0k

Revenue growth, %

247%

General and administrative expense

1.5m1.9m6.7m13.5m18.0m

R&D expense

5.1m9.2m24.5m41.5m57.0m
Quarterly
USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

45.0k442.0k657.0k548.0k367.0k505.0k71.0k

General and administrative expense

589.0k1.2m1.1m1.7m3.2m3.1m3.9m4.0m4.3m4.8m5.3m

R&D expense

2.1m4.7m5.2m6.9m7.3m10.3m11.8m13.9m12.6m13.7m17.6m

Operating expense total

2.7m6.0m6.3m8.6m10.4m13.3m15.7m17.9m16.9m18.5m22.9m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

12.2m14.2m73.7m40.3m93.1m

Prepaid Expenses

213.0k973.0k991.0k4.9m6.6m

Current Assets

12.4m15.2m74.7m123.3m177.5m

PP&E

224.0k400.0k476.0k3.9m3.2m
Quarterly
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(6.0m)(9.2m)(27.1m)(50.4m)(73.8m)

Depreciation and Amortization

92.0k128.0k471.0k887.0k948.0k

Accounts Payable

7.4m696.0k2.7m

Cash From Operating Activities

(5.5m)(9.5m)(19.5m)(46.4m)(62.0m)
Quarterly
USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(2.6m)(5.5m)(11.0m)(18.6m)(9.0m)(21.4m)(35.9m)(17.4m)(33.9m)(52.2m)(22.9m)

Depreciation and Amortization

27.0k48.0k124.0k263.0k200.0k430.0k658.0k235.0k479.0k723.0k224.0k

Accounts Payable

3.7m4.5m583.0k(92.0k)22.0k2.4m1.6m808.0k(271.0k)

Cash From Operating Activities

(2.3m)(3.4m)(7.8m)(13.4m)(6.8m)(19.3m)(32.9m)(12.2m)(28.1m)(46.1m)(20.1m)
USDFY, 2016

Revenue/Employee

31.0k

Financial Leverage

-2 x
Show all financial metrics

Crinetics Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Crinetics Pharmaceuticals Online and Social Media Presence

Embed Graph

Crinetics Pharmaceuticals News and Updates

Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Officer

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the app…

Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

- If successful, paltusotine would offer acromegaly patients a once-daily oral treatment option -

Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel

SAN DIEGO, June 16, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appo…

Crinetics Pharmaceuticals Announces Closing of Common Stock Offering

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it …

Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results

Webcast and conference call to take place on Tuesday, March 30, 2021 at 4:30 p.m. ET Webcast and conference call to take place on Tuesday, March 30, 2021 at 4:30 p.m. ET

Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021

Oral and Late-breaker Presentations Selected on the Company’s ACTH Antagonist and Congenital HI Programs Oral and Late-breaker Presentations Selected on the Company’s ACTH Antagonist and Congenital HI Programs
Show more

Crinetics Pharmaceuticals Blogs

CRN04777 Demonstrates Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study

CRN04777 Demonstrates Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study Alan Krasner, M.D., chief medical officer at Crinetics, added, “We are very encouraged by these single ascending dose data that clearly demonstrate…

Crinetics Reviews CRN04777 Phase 1 Single-ascending Dose Results

Crinetics Reviews CRN04777 Phase 1 Single-ascending Dose Results September 15, 2021 Aline Sherwood Crinetics Pharmaceuticals - Developing Therapies for Rare Endocrine Diseases -

Crinetics Appoints Jeff Knight as Chief Operating Officer

Crinetics Appoints Jeff Knight as Chief Operating Officer “Jeff’s intellectual curiosity and proven ability to grow into new roles makes him a natural fit for the Crinetics team. We look forward to applying his specific expertise in operational and clinical management as we continue to advance our …

Crinetics Reviews CRN04894 Single-Ascending Dose Results

Crinetics Reviews CRN04894 Single-Ascending Dose Results August 10, 2021 crineticspharmcms Crinetics Pharmaceuticals - Developing Therapies for Rare Endocrine Diseases -

Crinetics’ Second Quarter 2021 Financial Results and Corporate Update

Crinetics’ Second Quarter 2021 Financial Results and Corporate Update “We’ve seen advancements across our pipeline over the past months, with the commencement of dosing in the Phase 3 PATHFNDR-1 trial of paltusotine in acromegaly and the announcement of data from CRN04894’s Phase 1 program,” said S…

CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Strong Dose-Dependent Cortisol Suppression in Phase 1 Single Ascending Dose Study

CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Strong Dose-Dependent Cortisol Suppression in Phase 1 Single Ascending Dose Study Crinetics ($CRNX) today announced positive interim findings from the single ascending dose (SAD) arm of a first-in-human study with CRN04894 demonstrating pha…
Show more

Crinetics Pharmaceuticals Frequently Asked Questions

  • When was Crinetics Pharmaceuticals founded?

    Crinetics Pharmaceuticals was founded in 2008.

  • Who are Crinetics Pharmaceuticals key executives?

    Crinetics Pharmaceuticals's key executives are R. Scott Struthers, Marc Wilson and Alan S. Krasner.

  • How many employees does Crinetics Pharmaceuticals have?

    Crinetics Pharmaceuticals has 47 employees.

  • What is Crinetics Pharmaceuticals revenue?

    Latest Crinetics Pharmaceuticals annual revenue is $71 k.

  • What is Crinetics Pharmaceuticals revenue per employee?

    Latest Crinetics Pharmaceuticals revenue per employee is $1.5 k.

  • Who are Crinetics Pharmaceuticals competitors?

    Competitors of Crinetics Pharmaceuticals include Neopharmed Gentili, Macopharma and Alexion Pharmaceuticals.

  • Where is Crinetics Pharmaceuticals headquarters?

    Crinetics Pharmaceuticals headquarters is located at 10222 Barnes Canyon Rd Building #2, San Diego.

  • Where are Crinetics Pharmaceuticals offices?

    Crinetics Pharmaceuticals has an office in San Diego.

  • How many offices does Crinetics Pharmaceuticals have?

    Crinetics Pharmaceuticals has 1 office.